The effect of HMG-CoA reductase inhibitors on chronic allograft rejection

Contributions to Nephrology

Volumn 120, Issue , 1997, Pages 97-104

  Katznelson, Steven ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; LIPID; PRAVASTATIN;

ALLOTRANSPLANTATION; BLOOD; CLINICAL TRIAL; DRUG EFFECT; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HYPERLIPIDEMIA; IMMUNOLOGY; KIDNEY TRANSPLANTATION; REVIEW;

CLINICAL TRIALS; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIPIDS; PRAVASTATIN; TRANSPLANTATION, HOMOLOGOUS;

EID: 0030634167     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000059828     Document Type: Article

References (29)

1. Ballantyne CM, Radovancevic B, Farmer JA: Hyperlipidemia after heart transplantation: Report of a 6-year experience with treatment recommendations. J Am Coll Cardiol 1992;19:1315-1321.
2. Ong CS, Pollock CA, Caterson RJ, Mahony JF, Waugh DA, Ibels LS: Hyperlipidemia in renal transplant recipients: Natural history and response to treatment. Medicine 1994;73:215-223.
3. Kasiske BL, Guijarro C, Massy ZA, Wiederkehr MR, Ma JZ: Cardiovascular disease after renal transplantation. J Am Soc Nephrol 1996;7:158-165.
4. United States Renal Data System (USRDS) 1994: Annual Data Report. Bethesda, The National Institutes of Health: National Institutes of Diabetes and Digestive and Kidney Diseases, 1994.
5. Dimeny E, Fellstrom B, Larsson E, Tufveson G, Lithell H: Hyperlipoproteinemia in renal transplant recipients: Is there a linkage with chronic vascular rejection? Transplant Proc 1993:25:2065-2066.
6. Dimeny E, Tufveson G. Larsson E, Lithell H, Siegbahn A. Fellstrom B: The influence of posttransplant lipoprotein abnormalities on the early results of renal transplantation. Eur J Clin Invest 1993;23:572-579.
7. Isoniemi H, Nurminen M. Tikkanen MJ, von Willebrand E, Krogerus L, Ahonen J. Eklund B, Hockerstedt K, Salmela K, Hayry P: Risk factors predicting chronic rejection of renal allografts. Transplantation 1994:57:68-72.
8. Johnson MR: Transplant coronary disease: Nonimmunologic risk factors. J Heart Lung Transplant 1992;11:124-132.
9. Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang XM, Chia D, Terasaki PI, Sabad A, Cogert GA, Trosian K, Hamilton MA, Hage A, Drinkwater D, Stevenson LW: Impact of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995:333:621-627.
10. Katznelson S, Wilkinson AH, Kobashigawa JA, Wang WM, Chia D, Ozawa M, Zhong HP, Hirata M, Cohen AH,Terasaki PI, Danovitch GM: The effect of pravastatin on acute rejection after kidney transplantation. A pilot study. Transplantation 1996;61:1469-1474.
11. Paul LC, Fellstrom B: Chronic vascular rejection of the heart and the kidney. Have rational treatment options emerged? Transplantation 1992;53:1169-1179.
12. Tullius SG, Tilney NL: Both alloantigen-dependent and -independent factors influence chronic allograft rejection. Transplantation 1995:59:313-318.
13. Almond PS, Matas A, Gillingham K, Dunn DL, Payne WD, Gores P, Gruessner R, Najarian JS: Risk factors for chronic rejection in renal allograft recipients. Transplantation 1993:55:752-757.
14. Tullius SG, Heemann UW, Hancock WW: Long-term kidney isografts develop functional and morphological changes which mimic those of chronic allograft rejection. Ann Surg 1994:220:425-428.
15. Wenke K, Thiery J. Meiser BM, Arndtzn N, Seidel D, Reichart B: Reduction of graft vessel disease after heart transplantation by maximal treatment of hypercholesterolemia after heart transplantation (abstract). Am Soc Transplant Phys 1994, p 83.
16. Corsini A, Mazzotti M, Raiteri M: Relationship between mevalonatc pathway and arterial myocyte proliferation in in vitro studies with inhibitors of HMGCoA reductase. Atherosclerosis 1993;101:117-123.
17. Hidaka V, Eda T, Yonemoto M: Inhibition of cultured vascular smooth muscle cell migration by simvastatin (MK-733). Atherosclerosis 1992:95:87-92.
18. Meiser BM, Wenke K, Thiery J, Wolf S, Devens C, Seidel D, Hammer C, Billingham ME, Reichart B: Simvastatin decreases accelerated graft vessel disease after heart transplantation in an animal model. Transplant Proc 1993:25:2077-2079.
19. Schror K, Lopel P, Steinhagen-Thiessen E: Simvastatin reduces platelet thromboxane formation and restores normal platelet sensitivity against prostacyclin in type IIa hypercholesterolemia. Eicosanoids 1989;2:39-45.
20. Sahni R, Maniet AR, Voci G, Banka VS: Prevention of restenosis by lovastatin after successful coronary angioplasty. Am Heart J 1991;121:1600-1608.
21. Waters D, Higginson L, Gladstone P, and the CCAIT Study Group: Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative angiography: The Canadian Coronary Atherosclerosis Trial. Circulation 1994;89:959-968.
22. Ross R: The pathogenesis of atherosclerosis. An update. N Engl J Med 1986:314:488-499.
23. O'Donnell MP, Kasiske BL, Kim Y, Atluru D, Keane WF: Lovastatin inhibits proliferation of rat mesangial cells. J Clin Invest 1993:91:83-87.
24. Kasiske BL, O'Donnel MP, Garvis WJ, Keane WF: Pharmacologic treatment of hypcrlipidemia reduces glomerular injury in a rat 5/6 nephrectomy model of chronic renal failure. Circ Res 1988;62:367-374.
25. O'Donnell MP, Kasiske BL, Schmitz PG, Katz SA, Keane WF: Lovastatin but not enalapril reduces glomerular injury in Dahl salt-sensitive rats. Hypertension 1992:20:651-658.
26. Cutts JL, Scallen TJ, Watson J, Bankhurst AD: Role of mevalonic acid in the regulation of natural killer cell cytotoxicity. J Cell Physiol 1989;139:550-555.
27. Snapper CM, Yamaguchi H, Moorman MA, Sneed R, Smoot D, Mond JJ: Natural killer cells induce activated murine B cells to secrete Ig. J Immunol 1993;151:5251-5260.
28. Cutts JL, Bankurst AD: Suppression of lymphoid cell function in vitro by inhibition of 3-hydroxy-3-methylglutaryl enzyme A reductase by lovastatin. Int J Immunopharmacol 1989;11:863-868.
29. Kreuzer J, Bader J, Jahn L: Chemotaxis of the monocyte line U937: Dependence on cholesterol and early mevalonate pathway products. Atherosclerosis 1991:90:203-209.